Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension

Paul R. Eisenberg, Charles Lucore, Lisa Kaufman, Burton E. Sobel, Allan S Jaffe, Stuart Rich

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Although the mechanisms involved in the pathophysiology of primary pulmonary hypertension have not yet been delineated, thrombosis has been implicated. This study was designed to determine whether thrombin activity as reflected by plasma concentrations of fibrinopeptide A (FPA), a marker of the action of thrombin on fibrinogen, is increased in patients with primary pulmonary hypertension. To evaluate nbrinolytic activity, we measured plasma concentrations of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and cross-linked fibrin degradation products. We studied 31 patients with primary pulmonary hypertension. Plasma FPA concentrations measured by radioimmunoassay, were elevated to 87.4±36.9 ng/ml (mean±SEM). Fifteen minutes after administration of heparin (5,000 U), FPA concentrations decreased to 6.8±1.4 ng/ml (p<0.001 compared with preheparin levels). In 21 of 30 patients (70%), FPA concentrations after heparin administration were less than half the preheparin levels, a response consistent with inhibition of thrombin by heparin and the short half-life of FPA. Despite evidence for marked thrombin activity, plasma concentrations of cross-linked fibrin degradation products were normal in all but four patients. Plasminogen activator inhibitor-1 activity was elevated in 19 of the 27 patients in whom it was measured, potentially limiting the fibrinolytic response. The elevations of FPA indicate that thrombin activity is increased in vivo in patients with primary pulmonary hypertension. Thus, sequential assays of plasma markers of thrombosis and fibrinolysis in vivo may help identify those patients who may benefit from treatment with anticoagulants.

Original languageEnglish (US)
Pages (from-to)841-847
Number of pages7
JournalCirculation
Volume82
Issue number3
StatePublished - Sep 1990
Externally publishedYes

Fingerprint

Fibrinopeptide A
Blood Vessels
Thrombosis
Thrombin
Lung
Fibrin Fibrinogen Degradation Products
Heparin
Plasminogen Activator Inhibitor 1
Fibrinolysis
Tissue Plasminogen Activator
Familial Primary Pulmonary Hypertension
Anticoagulants
Fibrinogen
Radioimmunoassay
Half-Life

Keywords

  • Fibrin degradation products
  • Fibrinolysis
  • Fibrinopeptide A
  • Hypertension
  • Thrombosis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Eisenberg, P. R., Lucore, C., Kaufman, L., Sobel, B. E., Jaffe, A. S., & Rich, S. (1990). Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation, 82(3), 841-847.

Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. / Eisenberg, Paul R.; Lucore, Charles; Kaufman, Lisa; Sobel, Burton E.; Jaffe, Allan S; Rich, Stuart.

In: Circulation, Vol. 82, No. 3, 09.1990, p. 841-847.

Research output: Contribution to journalArticle

Eisenberg, PR, Lucore, C, Kaufman, L, Sobel, BE, Jaffe, AS & Rich, S 1990, 'Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension', Circulation, vol. 82, no. 3, pp. 841-847.
Eisenberg, Paul R. ; Lucore, Charles ; Kaufman, Lisa ; Sobel, Burton E. ; Jaffe, Allan S ; Rich, Stuart. / Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. In: Circulation. 1990 ; Vol. 82, No. 3. pp. 841-847.
@article{95a31cb88aa14d86b08cfa93d3b6a438,
title = "Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension",
abstract = "Although the mechanisms involved in the pathophysiology of primary pulmonary hypertension have not yet been delineated, thrombosis has been implicated. This study was designed to determine whether thrombin activity as reflected by plasma concentrations of fibrinopeptide A (FPA), a marker of the action of thrombin on fibrinogen, is increased in patients with primary pulmonary hypertension. To evaluate nbrinolytic activity, we measured plasma concentrations of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and cross-linked fibrin degradation products. We studied 31 patients with primary pulmonary hypertension. Plasma FPA concentrations measured by radioimmunoassay, were elevated to 87.4±36.9 ng/ml (mean±SEM). Fifteen minutes after administration of heparin (5,000 U), FPA concentrations decreased to 6.8±1.4 ng/ml (p<0.001 compared with preheparin levels). In 21 of 30 patients (70{\%}), FPA concentrations after heparin administration were less than half the preheparin levels, a response consistent with inhibition of thrombin by heparin and the short half-life of FPA. Despite evidence for marked thrombin activity, plasma concentrations of cross-linked fibrin degradation products were normal in all but four patients. Plasminogen activator inhibitor-1 activity was elevated in 19 of the 27 patients in whom it was measured, potentially limiting the fibrinolytic response. The elevations of FPA indicate that thrombin activity is increased in vivo in patients with primary pulmonary hypertension. Thus, sequential assays of plasma markers of thrombosis and fibrinolysis in vivo may help identify those patients who may benefit from treatment with anticoagulants.",
keywords = "Fibrin degradation products, Fibrinolysis, Fibrinopeptide A, Hypertension, Thrombosis",
author = "Eisenberg, {Paul R.} and Charles Lucore and Lisa Kaufman and Sobel, {Burton E.} and Jaffe, {Allan S} and Stuart Rich",
year = "1990",
month = "9",
language = "English (US)",
volume = "82",
pages = "841--847",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension

AU - Eisenberg, Paul R.

AU - Lucore, Charles

AU - Kaufman, Lisa

AU - Sobel, Burton E.

AU - Jaffe, Allan S

AU - Rich, Stuart

PY - 1990/9

Y1 - 1990/9

N2 - Although the mechanisms involved in the pathophysiology of primary pulmonary hypertension have not yet been delineated, thrombosis has been implicated. This study was designed to determine whether thrombin activity as reflected by plasma concentrations of fibrinopeptide A (FPA), a marker of the action of thrombin on fibrinogen, is increased in patients with primary pulmonary hypertension. To evaluate nbrinolytic activity, we measured plasma concentrations of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and cross-linked fibrin degradation products. We studied 31 patients with primary pulmonary hypertension. Plasma FPA concentrations measured by radioimmunoassay, were elevated to 87.4±36.9 ng/ml (mean±SEM). Fifteen minutes after administration of heparin (5,000 U), FPA concentrations decreased to 6.8±1.4 ng/ml (p<0.001 compared with preheparin levels). In 21 of 30 patients (70%), FPA concentrations after heparin administration were less than half the preheparin levels, a response consistent with inhibition of thrombin by heparin and the short half-life of FPA. Despite evidence for marked thrombin activity, plasma concentrations of cross-linked fibrin degradation products were normal in all but four patients. Plasminogen activator inhibitor-1 activity was elevated in 19 of the 27 patients in whom it was measured, potentially limiting the fibrinolytic response. The elevations of FPA indicate that thrombin activity is increased in vivo in patients with primary pulmonary hypertension. Thus, sequential assays of plasma markers of thrombosis and fibrinolysis in vivo may help identify those patients who may benefit from treatment with anticoagulants.

AB - Although the mechanisms involved in the pathophysiology of primary pulmonary hypertension have not yet been delineated, thrombosis has been implicated. This study was designed to determine whether thrombin activity as reflected by plasma concentrations of fibrinopeptide A (FPA), a marker of the action of thrombin on fibrinogen, is increased in patients with primary pulmonary hypertension. To evaluate nbrinolytic activity, we measured plasma concentrations of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and cross-linked fibrin degradation products. We studied 31 patients with primary pulmonary hypertension. Plasma FPA concentrations measured by radioimmunoassay, were elevated to 87.4±36.9 ng/ml (mean±SEM). Fifteen minutes after administration of heparin (5,000 U), FPA concentrations decreased to 6.8±1.4 ng/ml (p<0.001 compared with preheparin levels). In 21 of 30 patients (70%), FPA concentrations after heparin administration were less than half the preheparin levels, a response consistent with inhibition of thrombin by heparin and the short half-life of FPA. Despite evidence for marked thrombin activity, plasma concentrations of cross-linked fibrin degradation products were normal in all but four patients. Plasminogen activator inhibitor-1 activity was elevated in 19 of the 27 patients in whom it was measured, potentially limiting the fibrinolytic response. The elevations of FPA indicate that thrombin activity is increased in vivo in patients with primary pulmonary hypertension. Thus, sequential assays of plasma markers of thrombosis and fibrinolysis in vivo may help identify those patients who may benefit from treatment with anticoagulants.

KW - Fibrin degradation products

KW - Fibrinolysis

KW - Fibrinopeptide A

KW - Hypertension

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0025041322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025041322&partnerID=8YFLogxK

M3 - Article

C2 - 2394005

AN - SCOPUS:0025041322

VL - 82

SP - 841

EP - 847

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -